Postpartum cardiomyopathy (PPCM) is a disease of unknown etiology and exposes women to high risk of mortality after delivery despite optimal medical therapy. Experimental data suggested that enhanced oxidative stress promotes the proteolytical processing of the lactation hormone prolactin into a biologically active derivative, the 16kDa prolactin, which appears to be a major cause for PPCM. We observed increased oxLDL levels in a subset of these PPCM patients, indicative of oxidative stress, enhanced Cathepsin D activity and substantial levels of the cleaved 16kDa form of prolactin. We therefore propose that the excessive generation of 16kDa prolactin mediates PPCM in humans and suggest that inhibition of prolactin release may represent a novel therapeutic strategy for PPCM.
INTRODUCTION
Peripartum cardiomyopathy (PPCM) is a distinct entity of dilated cardiomyopathy that occurs in women between 1 month antepartum and 5 months postdelivery. (1, 2) The low incidence of PPCM in the northern hemisphere (1:15 000) as compared to countries like Nigeria,
Haiti and South Africa with an incidence between 1:100 to 1:1 000, (3) (4) (5) (6) (7) is one of the reasons why numerous previous studies on PPCM relied on case reports, small numbers of patients or a review of medical records. One option was even a survey among 15 000 members of the American College of Cardiology by mail (8) in an effort to obtain basic information that totaled 123 patients. (9) Only patients in Haiti were studied prospectively by the same group of doctors, but given the political situation, researchers were faced with practical and logistical diffi culties.
Many reports on PPCM were written before the advent of echocardiography, an essential investigation into the diagnosis of PPCM.
As a result, previous reports and studies most likely included a signifi cant percentage of patients with a non-PPCM cause of cardiac malfunction that clinically mimic heart failure. The criteria for PPCM were re-defi ned in 1997, (1) emphasizing the absence of other underlying cardiac conditions to help refi ne the diagnosis of human PPCM. This problem of inaccurate diagnosis is refl ected by the fact that select studies of human PPCM included a high percentage of patients with other cardiac conditions, e.g. a history of hypertension during pregnancy in 43% of patients. (9) Furthermore, ACE-inhibitors or β-blockers were not available during many of the early studies, impacting negatively on outcome.
In view of the above, systematic data collection to study the aetiology and the potential pathogenic mechanisms of PPCM was deemed diffi cult. The high incidence of PPCM at a single tertiary centre in South
Africa provided a unique opportunity to conduct a prospective study of the mechanism of the pathogenesis and clinical features of PPCM.
This enabled us to perform a translational study and novel therapeutic approach to treat patients with a high risk for PPCM. Based on data obtained from an animal model of PPCM (mice with a cardiomyocytespecifi c knock-out of signal transducer and activator of transcription
; stat3 fl ox/fl ox : STAT3-KO) (10) we emphasized that a biologically active degradation product of the nursing hormone prolactin might be a major cause of the development of PPCM.
Treatment with bromocriptine, a drug widely used to stop lactation in women, prevented PPCM completely in our mouse model. Interestingly, we discovered striking parallels between the prolactin based pathomechanism in STAT3-KO mice and patients with PPCM. (10) Based on these experimental fi ndings, a pilot trial with bromocriptine was started at our center, including 12 patients with a high risk for PPCM due to a PPCM in a previous pregnancy.
In summary, this review points out the systematic data collection and analysis of 100 patients with PPCM. In addition, we made use of our Heart Association (NYHA) functional class, echocardiography and details of the statistical analysis are described elsewhere. (11) Clinical profi le of 100 study patients with PPCM 
TRANSLATIONAL APPROACH FROM MOUSE TO (WO)MAN
A mouse model of PPCM (10) Furthermore, our study in Cell (10) 
Is prolactin the heart breaker in postpartum STAT3-KO mice?
Prolactin, a dominant hormone in pregnancy and early postpartum, has been suggested previously as a potential factor in the pathogenesis of PPCM. (16) Interestingly, prolactin can be cleaved by cathepsin D, a protease which is activated by oxidative stress in cardiomyocytes (17, 18) FIGURE 2: Baseline plasma infl ammatory markers of deceased patients vs. survivors. Only differences in Fas/Apo-1 were statistically signifi cant (p=0.002). In absence of cardiomyocyte STAT3 activity, oxidative stress (indicated by increased production of reactive oxidant species, ROS) is increased, leading to the release of Cathepsin D (CD) from the lysosome into the cytoplasm and the interstitium. There it processes 23kDa prolactin (Prl) into its detrimental 16kDa form. Subsequently, the 16kDa Prl promotes vasoconstriction, apoptosis in endothelial cells, capillary dissociation and interferes with cardiomyocyte metabolic activity, all of which subsequently leads to heart failure. Consequently, bromocriptine (BR), a pharmacological inhibitor of prolactin release, prevents PPCM in mice by excluding prolactin from the circulation. Cardiomyocyte into a 16-kDa form of prolactin, which is known to exert strong antiangiogenic effects such as endothelial cell dissociation and apoptosis. (19) We were able to demonstrate that left ventricular tissue displays a high cleavage activity for prolactin into its 16kDa form.
(10) Furthermore, we showed that the 16kDa prolactin, even in the absence of the postpartum physiology, decreased cardiac capillary density and cardiac function, thereby mimicking at least in part the cardiac phenotype of PPCM in our mouse model ( Figure 3 ). (10) To obtain further proof of whether or not the generation of the 16-kDa form of prolactin is involved in the development of PPCM as well as to test a potential novel therapeutic strategy, we treated STAT3-KO female mice for two consecutive pregnancies with bromocriptine, a dopamine-D2-receptor agonist, which inhibits prolactin secretion (administered 5 days before delivery and continued 3 weeks postpartum). Indeed, bromocriptine treatment of STAT3-KO female mice prevented the entire PPCM phenotype concerning postpartum mortality, cardiac angiogenesis, cardiac function, cardiac dilatation, as well as cardiac fi brosis and apoptosis. (10) In Figure 3 Indeed, the serum of lactating patients with PPCM contained increased levels of oxidized low density lipoprotein (oxLDL), a marker for oxidative stress (20) and increased Cathepsin D activity compared to healthy lactating women. (10) In addition, we were able to detect an antigen corresponding to the 16-kDa prolactin in the sera of 3 out of 5 lactating PPCM patients with obvious cardiac dysfunction at the time of serum sampling (mean %EF: 24±7), while no 16-kDa form of prolactin was detectable in healthy lactating women (n=5). (10) Bromocriptine treatment may prevent PPCM in high-risk patients PPCM occurs in previously healthy women who cannot be identifi ed prospectively. However, women with PPCM who recover normal cardiac function have a high risk for reoccurring PPCM. (21) We therefore studied 12 patients who had recovered from a previous episode of PPCM and presented with a subsequent pregnancy. (10) In these women echocardiography was performed before delivery (8 months of pregnancy) and 3 months post-delivery. Six of these patients received bromocriptine 2.5 bd. after giving birth and subsequently for 2 months post-delivery in addition to standard heart failure therapy. (10) Controls for this preliminary study consisted of 6 patients with subsequent pregnancies after a previous episode of PPCM who presented similar pre-delivery cardiac function and dimensions (Table 2 ) and received standard heart failure treatment only. (10) In all patients who received additional bromocriptine post-delivery prolactin serum levels were returned to non-pregnant levels within 14 days of treatment as described previously. (22) Moreover, all bromocriptine treated patients presented normalization of LV function and dimensions (Table 2 ) and survived the 4-month observation period. (10) In the control group, three patients had died and the surviving showed deterioration of LV function and marked dilatation of the left ventricle (Table 2) . Patients that died had lower NYHA FC, LVEF and larger left ventricular dimensions at diagnosis compared to those who survived, whereas age, parity or onset of symptoms did not appear to play a role. Demakis et al. found that pathological fi ndings in the myocardium of patients whose hearts had returned to normal size within six months of treatment and those whose hearts had not returned to normal size were indistinguishable. (25) CRP is an acute-phase protein which recognizes a range of pathogenic targets, including membranes of apoptotic and reactive cells. (26) As this infl ammatory marker is associated with adverse prognosis in patients with idiopathic dilated cardiomyopathy , (27, 28) we investigated if levels of plasma CRP at baseline could predict outcome in patients with PPCM.
Almost half of the population investigated had raised levels of CRP refl ecting possibly the presence of a low-grade chronic infl ammatory process due to the release of endotoxin or endotoxin-like substances and subsequent release of pro-infl ammatory cytokines. (29) However, we did not fi nd a correlation with NYHA FC or death. None of the patients with PPCM presented with symptoms during the antepartum period. This is in contrast to studies performed by others (30) and more in keeping with a study from Haiti (24) documenting that 96% of patients with PPCM developed heart failure in the postpartum period. Our failure to include PPCM patients during the prepartum period in the present study was not due to a lack of identifying such patients, since the cardiologists at Chris Hani Baragwanath Hospital are routinely involved in the care of pregnant patients presenting with symptoms and signs of congestive cardiac failure. The majority of cases developed symptoms in the fi rst 4 weeks postpartum. Twenty per cent of patients studied were primiparous. We could not confi rm factors mentioned by others (30) as multiparity, older age, or long-term use of tocolytic agents to be associated with the development of PPCM. At presentation, this group of patients had acute onset heart failure of short duration. There was no evidence of chronic disease or cardiac cachexia that could account for a low lipid profi le being a marker of severe, chronic disease.
Mean plasma levels of total cholesterol of the patient population studied was 4.2±0.8 mmol/L and low compared to that reported in other studies. (31) (32) (33) In a study by Rauchhaus and colleagues with an established plasma cholesterol cut-off level of < 5.2 mmol/L, low total cholesterol level was found to be predictive for impaired 1-year survival. (32) In line with fi ndings by others (31, 32) demonstrating an increase in the rate of mortality with low serum total cholesterol levels, we found an association of low total cholesterol levels with larger left ventricular dimensions and lower EF. There was a trend, but no statistically signifi cant association between the rate of mortality, which could possibly be explained by the short duration of the trial, the limited number of patients studied and the spontaneous recovery rate typical for patients with PPCM. Levels of low plasma cholesterol correlated positively with the levels of the infl ammatory marker CRP. These fi ndings are in support of the endotoxin-lipoprotein hypothesis (29) suggesting that lower plasma levels of total cholesterol provide lesser protection against endotoxins, making a susceptible group of patients more prone to severe heart failure. A recent trial by Albert and PATIENTS WITH PERIPARTUM CARDIOMYOPATHY colleagues (34) showed a signifi cant variation in the distribution of plasma CRP levels among various ethnic groups living in the United States.
Median plasma CRP levels were signifi cantly higher among black women compared to their white, Hispanic or Asian counterparts. Since 40% of the variance of plasma CRP levels is genetically determined and PPCM is much more frequent in black patients, one could hypothesize that an increase in the intensity of an infl ammatory response could be one of many factors contributing towards the development of PPCM. This is supported by our previous research in PPCM patients presenting with subsequent pregnancy, where we observed an exaggerated postpartum pro-infl ammatory cytokine surge possibly playing a role in the development of PPCM. Clinical studies have determined that bromocriptine is safe during pregnancy. (35) Our encouraging preliminary results in patients treated with a combination of bromocriptine and standard heart-failure therapy compared to patients treated with standard heart-failure therapy only could further support the hypothesis that the 16-kDa form of prolactin may represent a causal factor for development of PPCM in patients. (10) In conclusion, the well characterized profi le of 100 PPCM patients, in combination with basic science, enables a unique concept of translational research, which provides new insights into the pathomechanisms behind heart failure and, more specifi cally, PPCM. In addition, this concept may have contributed to a novel and more specifi c therapeutic option to treat patients with PPCM or prevent the disease in patients who suffered and recovered from PPCM in a previous pregnancy. However, additional data, mainly a controlled randomized study, is needed in order to determine the true value of bromocriptine as a specifi c novel therapy for PPCM.
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